Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

NCT06609356 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes Mellitus
Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)
MODY2 Diabetes
Healthy Volunteer

Interventions

PROCEDURE: Study Visit 1
DRUG: Placebo
PROCEDURE: Study Visit 2
DRUG: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

Sponsor

Vanderbilt University Medical Center